AcelRx Pharmaceuticals, Inc. (ACRX): Product News News

ACRX – Receives Complete Response Letter from the FDA regarding its New Drug Application for DSUVIA, 30 mcg.


Key Facts Surrounding This News Item


  • ACRX had a POWR Rating of A (Strong Buy) coming into today.
  • ACRX was 4.14% above its 10-Day Moving Average coming into today.
  • ACRX was 24.17% above its 20-Day Moving Average coming into today.
  • ACRX was 50.11% above its 50-Day Moving Average coming into today.
  • ACRX was 73.64% above its 100-Day Moving Average coming into today.
  • ACRX was 80.69% above its 200-Day Moving Average coming into today.
  • ACRX had returned +105.77% year-to-date leading up to today’s news, versus a +15.71% return from the benchmark S&P 500 during the same period.

More Info About AcelRx Pharmaceuticals, Inc. (ACRX)


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.
View our full ACRX ticker page with ratings, news, and more.

ACRX at a Glance

ACRX Current POWR Rating™
Overall POWR Rating™
ACRX Current Price $2.10 2.33%
More ACRX Ratings, Data, and News

ACRX Price Reaction

The day of this event (Oct. 12, 2017)
ACRX Closing Price$2.15 59.81%
ACRX Volume24,274,300
3,506.56% from avg
Leading up to this event
ACRX 1-mo return64.62%
After this event
ACRX 1-day return151.76%
ACRX 3-day return205.71%
ACRX 5-day return205.71%

ACRX Price Chart



More AcelRx Pharmaceuticals, Inc. (ACRX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ACRX News
Page generated in 0.7089 seconds.